Affymetrix Posts 12 Percent Revenue Drop, Amends Deal for eBioscience | GenomeWeb

NEW YORK (GenomeWeb News) – Affymetrix reported after the close of the market on Thursday that revenues in the first quarter dropped 12 percent year over year.

The Santa Clara, Calif.-based microarray company also announced separately that it has signed an amended deal to acquire eBioscience for $315 million in cash.

Affy's revenues for the three months ended March 31 dropped to $65.2 million, down from $73.7 million a year ago, but still above Wall Street estimates of $64.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.